Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Corticosteroid withdrawal Clear all
Completed Not applicable Interventional

Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors

NCT02200133
View directory record Official record
Conditions
Adult Hematopoietic Cell Transplant (HCT) Survivors 1-2 Yrs Post Most Recent HCT
Interventions
Individualized Survivorship Care Plan (SCP)
Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Scottsdale, Arizona • Gainesville, Florida • Maywood, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 21, 2026, 5:52 PM EDT
Terminated Not applicable Interventional Results available

Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

NCT01156480
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
hydrocortisone, placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
0 Days to 6 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 21, 2026, 5:52 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

NCT01878786
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA)
Drug
Lead sponsor
Matthew Cooper
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 21, 2026, 5:52 PM EDT
Terminated Phase 2 Interventional

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

NCT00023244
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 20 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional

The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers

NCT00900900
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
dehydroepiandrosterone (DHEA), pregnenolone, Placebo
Dietary Supplement · Drug
Lead sponsor
Jed E. Rose
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Results available

Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer

NCT05177042
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Bavdegalutamide, Abiraterone
Drug
Lead sponsor
Arvinas Androgen Receptor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional

A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients

NCT00650468
View directory record Official record
Conditions
Renal Transplantation
Interventions
tacrolimus, CellCept, steroids (methylprednisone or prednisone)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
29
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 21, 2026, 5:52 PM EDT
Terminated Phase 4 Interventional Results available

A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal

NCT02317276
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Triamcinolone 0.1%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

NCT02770807
View directory record Official record
Conditions
Nervous System Disease, Genetic Syndrome
Interventions
EryDex Low dose DSP, EryDex High dose DSP, Pooled Placebo
Drug
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 21, 2026, 5:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

NCT00953576
View directory record Official record
Conditions
Prostate Cancer
Interventions
ketoconazole, hydrocortisone, dutasteride, lapatinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Results available

Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients

NCT01336296
View directory record Official record
Conditions
Kidney Transplant Recipients
Interventions
mycophenolic acid
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional

A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

NCT00048152
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Corticosteroids, Neoral, Zenapax, mycophenolate mofetil [CellCept]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Results available

Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal

NCT00374803
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Mycophenolic Acid (Myfortic)
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 21, 2026, 5:52 PM EDT
Terminated Phase 2 Interventional Results available

An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma

NCT02219048
View directory record Official record
Conditions
Asthma
Interventions
Placebo, PF-03715455
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

NCT02878603
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura
Interventions
Caplacizumab, Standard of Care
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
St Louis, Missouri • Valhalla, New York • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional

Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease

NCT00056355
View directory record Official record
Conditions
Crohn Disease
Interventions
UVADEX and UVAR XTS Photopheresis System
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Not applicable Interventional

MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal

NCT00214279
View directory record Official record
Conditions
Renal Transplantation
Interventions
Corticosteroid withdrawal
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 21, 2026, 5:52 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Results available

Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients

NCT00374231
View directory record Official record
Conditions
Liver Transplantation
Interventions
tacrolimus, mycophenolate mofetil, Prednisone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Not applicable Interventional

Inflammatory Processes in the Airway of Asthmatics With Persistent Bronchial Hyperreactivity

NCT00217854
View directory record Official record
Conditions
Asthma
Interventions
Bronchoscopic
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

NCT00135694
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
Interventions
calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids, immunosuppression withdrawal
Drug · Procedure · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 21, 2026, 5:52 PM EDT
Terminated Phase 4 Interventional

Platelet-rich Plasma, Corticosteroid, or Lidocaine for Acromioclavicular Joint Pain

NCT05161468
View directory record Official record
Conditions
Acromioclavicular Sprain
Interventions
Lidocaine injection, Corticosteroid Injection, Protein Rich Plasma(PRP) Injection
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Not applicable Interventional

Calcineurin Inhibitor Based Immunosuppression Withdrawal

NCT02117596
View directory record Official record
Conditions
Renal Transplant
Interventions
Sirolimus
Drug
Lead sponsor
Pediatric Nephrology of Alabama
Other
Eligibility
Up to 19 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 21, 2026, 5:52 PM EDT
Recruiting Phase 2 Interventional

Belatacept in Heart Transplantation

NCT06478017
View directory record Official record
Conditions
Heart Transplant
Interventions
Belatacept, Tacrolimus, Mycophenolate Mofetil/Sodium, Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 76 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 5:52 PM EDT